Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. PagelChaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach

Research output: Contribution to journalArticlepeer-review

1 Citation (Web of Science)

Abstract

The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.

Original languageEnglish
Pages (from-to)603-608
Number of pages6
JournalClinical Cancer Research
Volume28
Issue number4
DOIs
Publication statusPublished - 15 Feb 2022

Fingerprint

Dive into the research topics of 'Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)'. Together they form a unique fingerprint.

Cite this